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.A clinical and family history study
of Parkinson’s disease in
heterozygous glucocerebrosidase
mutation carriers
Type I Gaucher disease (GD), the most
common lysosomal storage disorder, is caused
by recessive glucocerebrosidase mutations.1
Both patients with Type I GD and hetero-
zygous glucocerebrosidase mutation carriers
have increased Parkinson’s disease (PD) risk.1
Non-motor symptoms (NMS) are more
frequent in PD with heterozygous glucocer-
ebrosidase mutations (PD-GBA).2 We used
the non-motor symptoms scale (NMSS) and
Parkinson’s disease questionairre (PDQ-39) to
quantify NMS in PD-GBA.3 The age related
PD risk in heterozygous glucocerebrosidase
carriers has been reported in familial PD.4
Here, we calculate PD risk in obligate carrier
relatives (parents) of Type I GD patients.
Patients and methods
PD-GBA patients were identiﬁed by Sanger
sequencing of the glucocerebrosidase gene in
220 sporadic PD (PD-S) patients. The G2019S
mutation in LRRK2 had previously been
excluded. A control group of glucocere-
brosidase mutation negative PD-S were
selected from the same cohort. Each partici-
pant had the following administered: 40 item
smell identiﬁcation test (SIT), Montreal
Cognitive assessment (MoCA), Parts IeIV of
Uniﬁed Parkinson’s Disease Rating Scale
(UPDRS), NMSS, PDQ-39 and Rapid Eye
Movement (REM) Sleep Behaviour Disorder
Questionnaire (RBDQ). Statistical analysis
was performed using SPSS (version 17). The
proportion of participants with a MoCA score
<26/30 (signifying mild cognitive impair-
ment) or RBDQ >6/10 (signifying possible
REM sleep behaviour disorder) was compared
using the c2 test.3 In parallel, family history
data were obtained from 83 Type I GD
patients, detailing age of onset of PD in their
parents (n¼166, who are obligate carriers).
Age related risk of PD was calculated with
KaplaneMeier analysis. Parents with PDwere
also enrolled into the phenotyping study.
RESULTS
Of 220 PD patients sequenced, 12 (5.5%) had
a heterozygous glucocerebrosidase mutation,
and nine were available for follow-up. Three
parents of GD patients with PD were
recruited, giving a cohort of 12 PD-GBA
patients (5/12 female subjects, mean age 65
(range 49e81 years), 1/12 (8%) Ashkenazi
Jewish mean disease duration 8 years (range
2e15)). Twenty out of 208 PD patients
without glucocerebrosidase mutations (7/20
female subjects, mean age 65 (range
50e83 years), 2/20 Ashkenazi (10%) disease
duration 9 years (range 2e20 years)) were
selected as controls matched for age, sex and
disease duration. Mutations in the PD-GBA
group who underwent clinical phenotyping
were: N370S (5/12, 42%), L444P (2/12, 16%),
recombinant alleles (2/12, 16%), R496H (1/
12, 8.3%), V460L (1/12, 8.3%) and IVS2+1
(1/12, 8.3%). The groups were matched for
use of levo-dopa (75% vs 60%, p¼0.067) and
UPDRS parts I (PD-GBA median 8 vs PD-S 9,
p¼0.95), II (17 vs 18, p¼0.067), III (33 vs 34,
p¼0.13) and IV scores (1 vs 0, p¼0.13). No
patient had deep brain stimulation but two
PD-GBA patients were on selective serotonin
reuptake inhibitors for depression. All PD-
GBA and PD-S had olfactory dysfunction on
the SIT with no difference between group
medians (16/40 vs 15, p¼0.503). Using a cut-
off score of 26/30 on the MoCA, signiﬁcantly
more PD-GBA had cognitive impairment
than PD-S (7/12 (58%) vs 5/20 (25%),
p¼0.014). PD-GBA scores for abstraction
(mean 1.4 vs 2, p¼0.023) and orientation
(mean 5 vs 5.8, p¼0.016) were signiﬁcantly
lower, and there was a trend for PD-GBA
attention scores to be lower (mean 4.8 vs 5.5,
p¼0.055). The overall NMSS score was
higher for PD-GBA than PD-S (median 104
(IQR 69e134) vs 38 (16e60), p¼0.002). PD-
GBA reported more symptoms per partici-
pant than PD-S (median 13 (range 1e19) vs
median 7 (range 1e14), p¼0.0012). The
following were more common in PD-GBA:
falls with loss of consciousness (25% vs 0%,
p¼0.04), fatigue (92% vs 30%, p¼0.001),
unexplained pain (58% vs 10%, p¼0.005),
loss of interest in life (66% vs 5%, p¼0.0004),
anxiety (66% vs 20%, p¼0.02) and apathy
(50% vs 10%, p¼0.03). PDQ-39 summary
index scores were worse in PD-GBA than
PD-S (mean 37 (SD 25) vs mean 21 (SD 13),
p¼0.032). Subsections in which PD-GBA
Figure 1 KaplaneMeier analysis of age related risk of developing Parkinson’s disease. Risk is
derived from family history data on 166 obligate carriers of glucocerebrosidase mutations (parents
of Type I Gaucher disease patients), combined for men and women. Overall lifetime RR of
Parkinson’s disease was 30 (95% CI 7 to 122) in carriers compared to the London population.
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had worse scores were emotion (mean 12.5
vs 3.3, p¼0.008) and discomfort (mean 21.5
vs mean 6.3, p¼0.01) with cognition (mean
25 vs mean 12.5, p¼0.075) and ADL (mean
38.4 vs 21, p¼0.052) being non-signiﬁcantly
worse. Using a cut-off score of 6/10, more
PD-GBA participants screened positive for
REM sleep disorder than PD-S (7/12 (58%)
vs 1/20 (5%), p¼0.0016).
Data on 166 parents of Type I GD patients
were available (17/83 (20%) families Ashke-
nazi Jewish, 5/83 (6%) Eastern European and
the remainder Caucasian UK citizens, no
consanguineous families). A PD case was
deﬁned by the proband reporting a deﬁnite
medical diagnosis in their parents. Ten cases of
PD were identiﬁed, and three were examined
in person to conﬁrm diagnosis (these are
included in the cohort of 12 PD-GBA
described above). Of the 10 cases of PD in
relatives, ﬁve were male subjects (50%) and
mean age of onset was 67 (SD 8.6 years).
Figure 1 shows a KaplaneMeier analysis for
developing PD for men and women combined.
Age related risk of PD peaked at age 80 (15%).
Based on the London population,5 0.33 cases
of PD would be expected in our cohort of 166
(derived from lifetime prevalence of 2/1000 for
men and women). This gave a lifetime RR of
30 (95% CI 7 to 122).
DISCUSSION
Here, we conﬁrm reports of more severe
cognitive dysfunction, depression and
anxiety in PD-GBA.2 Using the NMSS and
PDQ-39, we demonstrate for the ﬁrst time
a greater burden of NMS, with lower quality
of life in PD-GBA. The number of NMS per
patient and severity of symptoms were
signiﬁcantly higher, even though both
groups were at a similar stage and duration
of PD. Interestingly, a positive result on the
RBD screening questionnaire was signiﬁ-
cantly more common in PD-GBA, suggesting
REM sleep behaviour disorder may be more
prevalent in PD-GBA. This needs conﬁrma-
tion with sleep studies. The midbrain raphe
is involved in sleep regulation and is more
frequently abnormal on transcranial sonog-
raphy in PD-GBA than PD-S.2 This may
explain the apparently increased REM sleep
behaviour disorder in PD-GBA. Olfactory
dysfunction in PD-GBA and PD-S was
equivalent. This contrasts with LRRK2 and
Parkin mutation associated PD in which
olfactory dysfunction is less severe than in
PD-S.3 This suggests that the pathological
process in PD-GBA and PD-S involves
olfactory pathways to a similar extent. The
more severe cognitive dysfunction in PD-
GBA implies that there may be more wide-
spread cortical pathology than in PD-S. Our
clinical ﬁndings of more severe NMS corre-
late with pathological studies indicating that
PD-GBA may be associated with more
widespread Lewy body pathology.1
Lifetime RR of PD in our cohort of 166
obligate carriers was 30, with a cumulative
risk of 5% at age 60 rising to 15% at age 80.
This risk is similar to that for Type I GD
patients.1 The risk in our cohort is less than
the 13.7% (age 60) and 29.7% (age 80)
reported in familial PD-GBA.4 It may be that
additional genetic or environmental factors
in these PD-GBA families are contributing to
an increased risk compared with our GD
families. Taken together, these studies
conﬁrm a high, age related risk of PD in
heterozygous carriers which may differ with
ethnic group and family history of GD. This
will help to inform genetic counselling of
parents of patients with Type I GD.
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